The combination of homocysteine and C-reactive protein predicts the outcomes of Chinese patients with parkinson's disease and vascular parkinsonism

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Zhang, Limin ^a   Yan, Junqiang ^a   Xu, Yunqi ^a   Long, Ling ^a   Zhu, Cansheng ^a   Chen, Xiaohong ^a   Jiang, Ying ^a   Yang, Lijuan ^a   Bian, Lianfang ^a   Wang, Qing ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HOMOCYSTEINE; LEVODOPA;

ADULT; ARTICLE; CHINESE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; MOTOR DYSFUNCTION; NONMOTOR SYMPTOMS SCALE; OUTCOME ASSESSMENT; PARKINSON DISEASE; PARKINSONISM; PREDICTION; PROTEIN BLOOD LEVEL; RATING SCALE; SYMPTOM; VASCULAR DISEASE; VASCULAR PARKINSONISM; AGED; BLOOD; CHINA; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; C-REACTIVE PROTEIN; CHINA; CROSS-SECTIONAL STUDIES; FEMALE; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PARKINSONIAN DISORDERS; VASCULAR DISEASES;

EID: 79955697142     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019333     Document Type: Article

References (40)

1. Chen H, O'Reilly EJ, Schwarzschild MA, Ascherio A, (2008) Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am J Epidemiol 167 (1): 90-95.
2. Saiki M, Baker A, Williams-Gray CH, Foltynie T, Goodman RS, et al. (2010) Association of the human leucocyte antigen region with susceptibility to Parkinson's disease. J Neurol Neurosurg Psychiatry 81 (8): 890-891.
3. Seet RC, Lee CY, Lim EC, Tan JJ, Quek AM, et al. (2010) Oxidative damage in Parkinson disease: Measurement using accurate biomarkers. Free Radic Biol Med 48 (4): 560-566.
4. Przedborski S, (2010) Inflammation and Parkinson's disease pathogenesis. Mov Disord 25 (Suppl 1): S55-57.
5. Song IU, Chung SW, Kim JS, Lee KS, (2010) Association between high-sensitivity C-reactive protein and risk of early idiopathic Parkinson's disease. Neurol Sci In press.
6. Song IU, Kim JS, Chung SW, Lee KS, (2009) Is there an association between the level of high-sensitivity C-reactive protein and idiopathic Parkinson's disease? A comparison of Parkinson's disease patients, disease controls and healthy individuals. Eur Neurol 62 (2): 99-104.
7. Rodriguez-Oroz MC, Lage PM, Sanchez-Mut J, Lamet I, Pagonabarraga J, et al. (2009) Homocysteine and cognitive impairment in Parkinson's disease: a biochemical, neuroimaging, and genetic study. Mov Disord 24 (10): 1437-1444.
8. Zoccolella S, dell'Aquila C, Abruzzese G, Antonini A, Bonuccelli U, et al. (2009) Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia. Mov Disord 24 (7): 1028-1033.
9. Müller T, Kuhn W, (2009) Homocysteine levels after acute levodopa intake in patients with Parkinson's disease. Mov Disord 24 (9): 1339-1343.
10. Müller T, Kuhn W, (2009) Cysteine elevation in levodopa-treated patients with Parkinson's disease. Mov Disord 24 (6): 929-932.
11. Zoccolella S, dell'Aquila C, Specchio LM, Logroscino G, Lamberti P, (2010) Elevated homocysteine levels in Parkinson's Disease: is there anything besides L-dopa treatment? Curr Med Chem 17 (3): 213-221.
12. Camicioli RM, Bouchard TP, Somerville MJ, (2009) Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients. Mov Disord 24 (2): 176-182.
13. Louis ED, Schupf N, Tang MX, Marder K, Luchsinger JA, (2007) Mild parkinsonian signs and plasma homocysteine concentration in community-dwelling elderly individuals. Arch Neurol 64 (11): 1646-1651.
14. Pfeiffer RF, (2009) Parkinson disease. Nonmotor symptoms in Parkinson disease: the PRIAMO study. Nat Rev Neurol 5: 531-532.
15. Li H, Zhang M, Chen L, Zhang J, Pei Z, et al. (2010) Nonmotor symptoms are independently associated with impaired health-related quality of life in Chinese patients with Parkinson's disease. Mov Disord In press.
16. Hughes AJ, Daniel SE, Kilford L, Lees AJ, (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181-184.
17. Zijlmans JC, Daniel SE, Hughes AJ, Révész T, Lees AJ, (2004) Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov Disord 19 (6): 630-640.
18. Klepac N, Hajnsek S, Trkulja V, (2010) Impact of pre-morbid depression on health-related quality of life in non-demented Parkinson's disease patients. Parkinsonism Relat Disord 16: 21-27.
19. Folstein MF, Folstein SE, McHugh PR, (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
20. Benamer HT, Grosset DG, (2009) Vascular parkinsonism: a clinical review. Eur Neurol 61 (1): 11-15 Review.
21. Fahn S, Elton R, Members of the UPDRS development committee (1987) The unified Parkison disease rating scale. Macmillan Health Care Information. Recent developments in Parkinson's disease 153-163 and 293-304.
22. Hoehn MM, Yahr MD, (1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427-442.
23. Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, et al. (2007) The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. Mov Disord 22: 1901-1911.
24. Ichihara Y, Ohno J, Suzuki M, Anno T, Sugino M, et al. (2002) Higher C-reactive protein concentration and white blood cell count in subjects with more coronary risk factors and/or lower physical fitness among apparently healthy Japanese Circ J 66 (7): 677-684.
25. Swinscow D, (1997) Correlation and regression Statistics at square one, 9th ed University of Southampton: BMJ Publishing Group.
26. Kalra S, Grosset DG, Benamer HT, (2010) Differentiating vascular parkinsonism from idiopathic Parkinson's disease: a systematic review. Mov Disord 25 (2): 149-156.
27. Winikates J, Jankovic J, (1999) Clinical correlates of vascular parkinsonism. Arch Neurol 56 (1): 98-102.
28. Zijlmans J, Evans A, Fontes F, Katzenschlager R, Gacinovic S, et al. (2007) [123I] FP-CIT spect study in vascular parkinsonism and Parkinson's disease. Mov Disord 22 (9): 1278-1285.
29. Critchley M, (1929) Arteriosclerotic parkinsonism. Brain 52: 23-83.
30. Prins ND, Den Heijer T, Hofman A, Koudstaal PJ, Jolles J, et al. (2002) Homocysteine and cognitive function in the elderly: the Rotterdam Scan Study. Neurology 59: 1375-1380.
31. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, et al. (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 346: 476-483.
32. Kjaergaard AD, Bojesen SE, Johansen JS, Nordestgaard BG, (2010) Elevated plasma YKL-40 levels and ischemic stroke in the general population. Ann Neurol 68 (5): 672-680.
33. Rogers JD, Sanchez-Saffon A, Frol AB, Diaz-Arrastia R, (2003) Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol 60 (1): 59-64.
34. Zijlmans JC, Thijssen HO, Vogels OJ, Kremer HP, Poels PJ, et al. (1995) MRI in patients with suspected vascular parkinsonism. Neurology 45: 2183-2188.
35. Zijlmans JC, Katzenschlager R, Daniel SE, Lees AJ, (2004) The L-dopa response in vascular parkinsonism. J Neurol Neurosurg Psychiatry 75 (4): 545-547.
36. Dufek M, Hamanová M, Lokaj J, Goldemund D, Rektorová I, et al. (2009) Serum inflammatory biomarkers in Parkinson's disease. Parkinsonism Relat Disord 15 (4): 318-320.
37. O'Suilleabhain PE, Sung V, Hernandez C, Lacritz L, Dewey RB Jr, et al. (2004) Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol 61 (6): 865-868.
38. Lamberti P, Zoccolella S, Iliceto G, Armenise E, Fraddosio A, et al. (2005) Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients. Mov Disord 20 (1): 69-72.
39. Lamberti P, Zoccolella S, Armenise E, Lamberti SV, Fraddosio A, et al. (2005) Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration. Eur J Neurol 12 (5): 365-368.
40. Barone P, Burn DJ, van Laar T, Hsu C, Poewe W, et al. (2008) Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients. Mov Disord 23: 1532-1540.